Optimer's Fidaxomicin Among Three NMEs Given Positive Review By Europe's Regulators
This article was originally published in The Pink Sheet Daily
Executive Summary
EU's scientific advisory panel also recommends approval for Takeda's azilsartan and Tibotec's rilpivirine, and grants positive opinions on new indications for Bayer/Johnson & Johnson's rivaroxaban and Alexion's eculizumab.
You may also be interested in...
Optimer's Early Sales Of Dificid Topping Analyst Projections
The anti-clostridial antibiotic, approved by FDA in May, is seeing rapid early adoption by hospital formularies.
Optimer's Early Sales Of Dificid Topping Analyst Projections
The anti-clostridial antibiotic, approved by FDA in May, is seeing rapid early adoption by hospital formularies.
Alexion's Soliris Gains New Orphan Indication But Limited Sales Expectations
The devastating natural course of atypical hemolytic uremic syndrome, coupled with the small quantity of drug used to treat pediatric patients, means the new use is expected to have only a small impact on sales initially, Alexion's management says.